Why Oculis Holding (OCS) Is Up 15.3% After FDA Breakthrough Status For Privosegtor In Optic Neuritis
Oculis Holding AG recently reported that its neuroprotective candidate Privosegtor received U.S. FDA Breakthrough Therapy designation for optic neuritis, supported by positive Phase 2 ACUITY data and ...
Privosegtor is advancing in the registrational PIONEER program across 2 key optic neuropathies, representing an unaddressed potential market of $7 billion in the U.S. Privosegtor achieved an average ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results